Anti-BCMA CAR T-cell therapy has shown impressive anti-myeloma activities (81–100%) in certain preclinical and/or clinical investigations.[3] Because of its high efficiency, some investigators are trying to move this type of treatment forward, such as in the consolidation of high-risk MM. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.